ACT now, ACT together to accelerate the end of the COVID-19 crisis
Updates

1. Release of ACT-Accelerator Strategy & Budget for 2021

2. Major upcoming events
   • Facilitation Council pre-briefing (19 March)
   • 5th Facilitation Council Meeting (23 March)

3. COVAX roll-out & risks
The ACT-Accelerator is evolving in a rapidly changing world....

...the new strategy for 2021 reflects these changes.
Major aspects of the new ACT-A plan for 2021....

1. Sharper Strategic & Pillar priorities
2. Sequencing of priority activities in 2021
3. Updated needs & financing gap

**Pillar achievements 2020**

**Complementary financing**

**Financing framework & accountabilities**

WHO SPRP, CEPI Investment Case and other ACT-A agency plans fully aligned

1. US $2.5 billion, UK $1.1 billion, Germany $2.6 billion, France $0.160 billion, Norway $0.470 billion, Japan $0.306 billion, Total $11 billion
In 2021 ACT-A has 4 strategic priorities, driving for equity, while continuously improving these tools

1. Rapidly scale-up delivery of >2 B vaccine doses
2. Bolster R&D, eval & reg paths to address variants & optimize products
3. Stimulate rapid uptake of tests, therapeutics & PPE
4. Ensure robust supply pipeline of essential tests, treatment & PPE

Pillar-specific priorities & deliverables underpin the 4 cross-cutting, strategic priorities
Pillar-specific priorities for 2021

**Vaccines**
1. deliver >2 B doses thru COVAX Facility in 2021, with >1.3 B in AMC countries, to cover initial high-risk target groups:
2. **Support country ambitions to end pandemic** (eg expand coverage & capacity, starting with >500 m add’l doses in ‘21)
3. Ensure equitable access & fair allocation of vaccines
4. Accelerate & expand R&D for programmaticallly-optimized vaccines that also address risks due to variants

**Diagnostics**
1. **Ensure equitable access to new and existing tests, incl. distribution of at least 900 million molecular and Ag-RDTs**
2. Stimulate rapid and effective uptake of appropriate and quality-assured diagnostics in countries
3. Drive development and at-scale availability of affordable, transformative, digitally-integrated tests.

**Therapeutics**
1. **Ensure uptake of existing products, incl. oxygen and corticosteroids for up to 12 m severe & critical patients**
2. Introduce new therapies for 100 m treatment courses across all use cases, subject to evidence and availability
3. Accelerate & intensify research to expand the clinical pipeline, broadening the portfolio of effective tools, incl. combinations of therapeutics

**Health Systems Connector**
1. Fully integrate the work and products of the Pillars with a strengthened, ongoing COVID-19 response
2. Rapidly address country health systems bottlenecks to ensure readiness, rapid scale up & delivery of tools
3. Accelerate PPE availability & use as a crucial tool to protect health workers and ensure resilience health system
4. Manage linkages with complementary activities in essential health services & HSS
Recognizing ACT-A’s generous contributors & updating the gap

A broad coalition of public (87%), private (6%) & multilateral donors (7%)

**ACT-A contributors** as of 11 March 2021

**ACT-A US$22.1 B financing gap for 2021**

Note: all financial commitments can be accessed at [https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker).

1. US$ 11 billion include $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs

2. Contributions <US$ 12m, and including $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs
Major Upcoming ACT-A Events
5th ACT-A Facilitation Council
23 March 2021, 12:30-15:00hr CET (Geneva time)

AGENDA FOCUS:

1. Achieving our ACT-A diagnostics & therapeutics goals for 2021: what’s holding us back?
   - Facilitated panel discussion with Council Members

2. Where do we have to focus to rapidly scale up vaccine supply to COVAX?
   - Interactive panel with CEPI, WHO, Countries, CSOs & Council

Proceeding will be livestreamed for all Member States on the ACT Accelerator site
Technical Pre-briefing:

- Date: Friday, 19 March, 12:30-14:00 hr CET (Geneva time)
- Focus: COVID-19 Diagnostics & Therapeutics - state of play & next steps
- Invitees: Council Members & WHO Member States (Permanent Missions)
- Format: overview presentations and Q&A

Member State delegations can register [HERE](#)
COVAX Rollout, Risks & Scale-up
1st wave of COVAX deliveries kicked off 24 February

24 February
The first batch of COVAX doses has arrived in Ghana (600,000 doses)

26 February
South Korea receives 117,000 COVAX doses

26 February
504,000 doses have landed in Côte d’Ivoire

1 March
Côte d’Ivoire and Ghana start their first COVID-19 COVAX vaccinations

2 March
3.94 million doses of COVAX vaccines arrive in Nigeria

SOURCE: GAVI
30 m COVAX doses delivered to 36 countries in just 2 weeks

- More shipments in coming days & weeks
- Planned shipments for next 7 days available on UNICEF Vaccine market dashboard (see “Delivery” tab)

SOURCE: GAVI
COVID-19 Vaccine Rollout: current status

NEW: WHO COVID-19 dashboard now includes vaccination

Globally, as of 10:16am CET, 10 March 2021, there have been 117,132,788 confirmed cases of COVID-19, including 2,600,839 deaths, reported to WHO. As of 9 March 2021, a total of 268,205,245 vaccine doses have been administered.


**COVAX rollout to date:** 30 m doses delivered to 36 countries

Number of COVAX deliveries, by date, as of 11 March 2021

Cumulative doses delivered, by supplier, as of 11 March 2021

1 an additional 10m doses supplied to India through COVAX
COVID-19 Vaccines Rollout (at 11 March)

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

SOURCE: COVAX, WHO COVID-19 dashboard, Our World in Data; Press research
NEW: Public COVAX roll-out dashboard resources

1. UNICEF for POs and planned shipments
   https://www.unicef.org/supply/covid-19-vaccine-market-dashboard

2. Gavi for deliveries
   https://www.gavi.org/live/covax-vaccine-roll-out
Scaling & Sustaining the COVAX Rollout – key risks at 10 March

1. Manufacturer level:

   **Serum Institute of India** (suppliers to 60 COVAX countries) – sustaining volumes

   **AstraZeneca/SK Bio** (supplier to 85 COVAX countries) - packaging & shipping capacity

   **Pfizer** (supplier to an initial 18 COVAX countries) - I&L & shipping capacity

2. Country level:

   13 of the COVAX participants that have not yet started vaccination, still lack key pre-requisites (e.g. I&L, regulatory authorization, financing)

The biggest risk to COVAX rollout to LMIC/LICs is the increasing competition & demand on key COVAX suppliers (i.e. SII, AZ)